Who is sponsoring NCT05779059?

NCT05779059 is sponsored by Collegium Medicum w Bydgoszczy.

What drugs are being tested in NCT05779059?

Interventions in NCT05779059: De-escalation to ticagrelor 60 mg at day 30, De-escalation to prasugrel 5 mg at day 30, Switch to ticagrelor 60 mg at day 45, Switch to prasugrel 5 mg at day 45.

What condition does NCT05779059 study?

NCT05779059 studies Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina.

Is NCT05779059 still recruiting?

NCT05779059 is currently status unknown. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT05779059: PROTEUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prasugrel Or Ticagrelor De-escalation in NSTE-ACS

Status unknown Phase 3 Last updated 22 March 2023

What this trial tests

Phase 3 trial testing De-escalation to ticagrelor 60 mg at day 30 in Non ST Segment Elevation Acute Coronary Syndrome in 50 participants. Status unknown.

Timeline

1 April 2023

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Collegium Medicum w Bydgoszczy
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 April 2023
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Poland

Drugs / interventions tested

De-escalation to ticagrelor 60 mg at day 30 — full drug profile →
De-escalation to prasugrel 5 mg at day 30 — full drug profile →
Switch to ticagrelor 60 mg at day 45 — full drug profile →
Switch to prasugrel 5 mg at day 45 — full drug profile →

Conditions studied

Non ST Segment Elevation Acute Coronary Syndrome — all drugs for Non ST Segment Elevation Acute Coronary Syndrome →
Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) — all drugs for Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) →
Unstable Angina — all drugs for Unstable Angina →

Sponsor

Collegium Medicum w Bydgoszczy — full company profile →

Who can join

Adults 18 to 75, any sex, with Non ST Segment Elevation Acute Coronary Syndrome or Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PROTEUS study is a randomized, cross-over, open-label, pharmacodynamic trial designed to compare the antiplatelet effect of reduced maintenance doses of prasugrel and ticagrelor in stable patients who recently had non-ST-elevation acute coronary syndrome (non-ST-elevation myocardial infarction or unstable angina).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Platelet biology and function: plaque erosion vs. rupture.
Baaten CCFMJ, Nagy M, Bergmeier W, Spronk HMH, et al · · 2024 · cited 70× · PMID 37940193 · DOI 10.1093/eurheartj/ehad720

Verify or expand the search:

Other recruiting trials for Non ST Segment Elevation Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06695429 — Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary · NA · recruiting
NCT06197724 — MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients · recruiting
NCT06255678 — Angio-based Final Functional Effect of PCI · recruiting
NCT05117866 — Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study · NA · active not recruiting

Other Collegium Medicum w Bydgoszczy trials

Trials by the same sponsor.

NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
NCT07231939 — Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI · recruiting
NCT05905965 — Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment · Phase 3 · recruiting
NCT04718025 — Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndro · Phase 3 · unknown
NCT05162456 — Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantat · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05779059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Collegium Medicum w Bydgoszczy
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05779059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing